Bevacizumab/ranibizumab/verteporfinGeographic atrophy: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1536卷 / 1期

关键词：

D O I：

10.1007/s40278-015-6902-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：49 / 49

相关论文

共 50 条

[1] VerteporfinGeographic atrophy and lack of efficacy: 2 case reports
Reactions Weekly, 2023, 1987 (1) : 231 - 231
[2] Bevacizumab/ranibizumab/triamcinoloneEndophthalmitis: 21 case reports
Reactions Weekly, 2011, 1377 (1) : 11 - 11
[3] Bevacizumab/ranibizumab/verteporfinLack of efficacy: 2 case reports
Reactions Weekly, 2023, 1954 (1) : 119 - 119
[4] Bevacizumab/temozolomideHippocampal atrophy: 13 case reports
Reactions Weekly, 2018, 1684 (1) : 55 - 55
[5] Bevacizumab/ranibizumab/triamcinoloneEndophthalmitis following intravitreal administration: 19 case reports
Reactions Weekly, 2012, 1419 (1) : 12 - 12
[6] Bevacizumab/paclitaxelLiver failure and liver atrophy: 6 case reports
Reactions Weekly, 2017, 1633 (1) : 126 - 126
[7] Bevacizumab/paclitaxelDysphonia: 4 case reports
Reactions Weekly, 2014, 1518 (1) : 47 - 47
[8] PhenytoinCerebellar atrophy: 4 case reports
Reactions Weekly, 2017, 1646 (1) : 270 - 270
[9] Bevacizumab/ranibizumabGeographic atrophy after intravitreal injection: 3 case reports
Reactions Weekly, 2015, 1536 (1) : 48 - 48
[10] Bevacizumab/pazopanibVarious toxicities: 4 case reports
Reactions Weekly, 2019, 1758 (1) : 79 - 79

← 1 2 3 4 5 →